SCHEMBL25320626

SCHEMBL25320626

C[C@H]1CCC(c2ccc3ccccc3c2)=NC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAOA P21397 5/20 0.43
▸ MAOB P27338 5/20 0.43
▸ NISCH Q9Y2I1 1/20 0.40
▸ ACHE P22303 2/20 0.37
▸ MAPK10 P53779 1/20 0.37
▸ NOS3 P29474 1/20 0.37
▸ NOS1 P29475 1/20 0.37
▸ NOS2 P35228 1/20 0.37
▸ GSK3B P49841 1/20 0.36
▸ GSTP1 P09211 1/20 0.36
▸ ESR1 P03372 1/20 0.36
▸ ESR2 Q92731 1/20 0.36
▸ CYP1A2 P05177 2/20 0.36
▸ CYP17A1 P05093 1/20 0.36
▸ CYP19A1 P11511 1/20 0.36
▸ CYP11B1 P15538 1/20 0.36
▸ CYP11B2 P19099 1/20 0.36
▸ ALDH1A1 P00352 1/20 0.36
▸ CYP3A4 P08684 1/20 0.36
▸ CYP2C9 P11712 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31578497 1.00 MAOA (0.43) MAOAMAOBNISCHACHEMAPK10
SCHEMBL25320632 1.00 MAOA (0.43) MAOAMAOBNISCHACHEMAPK10
SCHEMBL25335444 0.84 NOS3 (0.34) MAOAMAOBNOS3NOS1NOS2
SCHEMBL25335450 0.84 NOS3 (0.34) MAOAMAOBNOS3NOS1NOS2
SCHEMBL29081982 0.82 PRKCZ (0.38) GSK3BCYP11B1CYP11B2
SCHEMBL30470736 0.82 PRKCZ (0.38) GSK3BCYP11B1CYP11B2
SCHEMBL25323632 0.81 GSK3B (0.43) GSK3BCYP1A2ALDH1A1NPC1RAB9A
SCHEMBL25319298 0.81 NPC1 (0.53) GSK3BCYP1A2ALDH1A1CYP3A4TSHR
SCHEMBL31578433 0.81 GSK3B (0.43) GSK3BCYP1A2ALDH1A1NPC1RAB9A
SCHEMBL25323626 0.81 GSK3B (0.43) GSK3BCYP1A2ALDH1A1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250163048-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2025-05-22 — — US disclosed
EP-4469455-A1 COMPOUNDS AND METHODS OF USE Tango Therapeutics, Inc. (US) 2024-12-04 — — EP disclosed
WO-2023146990-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. (US) 2023-08-03 — — WO disclosed
WO-2023146990-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. (US) 2023-08-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250163048-A1 COMPOUNDS AND METHODS OF USE RB1, CYP1B1, REN MAOA 552/4885MAOB 135/4885NISCH 1021/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback